about
Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemiaDifferential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysisA subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyBiological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspectiveExpression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocolsIKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.PHF6 mutations in T-cell acute lymphoblastic leukemiaIdentification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling.Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors.Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trialDiagnostic tool for the identification of MLL rearrangements including unknown partner genesClassification of pediatric acute myeloid leukemia based on miRNA expression profiles.Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia.Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.Obesity is underestimated using body mass index and waist-hip ratio in long-term adult survivors of childhood cancer.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseExpression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9.Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemiaCharacterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients.The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaMethotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.Pediatric aggressive fibromatosis: a retrospective analysis of 13 patients and review of literature.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyThe significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemiaTowards targeted therapy for infant acute lymphoblastic leukaemia.The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.
P50
Q24597084-A092C492-040C-4627-8D46-734019100221Q24646189-4CDC7D1F-37FC-4312-AC74-A72CC1DC6F79Q24651897-2F8E8BAE-46A8-4A65-B937-B7412C505B83Q24658389-6B64BBBF-8B2E-4D2D-9D6F-8ABE9D1E964CQ24685883-9A32A212-ED88-4F2D-B1C7-95C264ED2059Q27852750-63317AF8-AEEB-4795-8FCC-BE6AE94A6CB1Q29394463-41301B8D-B081-4910-9396-175D8ADB4406Q30817570-18E504F0-C5D6-480B-88F0-CCD8E91F393FQ33193164-B140D934-B41A-468C-9F81-0089948BE54DQ33573735-4D9516C6-D514-42D9-8819-EAE333596283Q33655100-846090D2-9508-49A3-A0E1-ED901DD8500AQ33723050-9D0A36E9-7A0A-4667-BDDC-35466774DDA5Q33779361-CDDA6974-D429-4425-A6D7-2D4D252174BFQ33829083-A5CE3D12-3C90-4384-87D4-DA18B2807851Q33952766-7FEBDBA3-A75F-44E4-A3D4-FDC5C1E129CFQ34213539-57A63560-4108-40AE-8041-6B686A43BF5FQ34384933-1D5EF4E5-6B02-4904-9E72-9E915FF12399Q34400424-F5CDCF94-F5A1-4819-B88A-3C8E791E3355Q34412237-AFED9945-A5D9-4B42-8E27-DEFCE0ADF62CQ34463641-871772A5-24D6-42D3-84B4-036A87C4137EQ34488796-17B63DD5-FBC1-44FC-8B90-904604E8BF6FQ34517703-DDA7FF71-94AC-4F0D-ABEE-FE4D66B938F8Q34518952-5BAEF65F-2304-46ED-8EC6-FD81529643C4Q34542996-939EA034-1596-43F5-A004-980E6747E78BQ34612599-34B161BE-932C-414C-9D1B-EC718090CB72Q34778529-E5867BB6-C4D0-4106-ABAE-23BB5DF71A5DQ34798033-43F659C7-1159-4D0F-9271-5A9250B3AC52Q35146272-F2DB333B-4C4E-43C9-B27D-0987050A596DQ35202285-0FEECC00-8D71-4DEE-BC43-903B6DA28B30Q35265916-34B0522C-F882-4CFA-9F1E-3B9490B6106FQ35684384-99922890-FC80-4FB5-B423-CF69DB6E1009Q35781265-09C66E72-3534-4B1E-845E-38CDB06E4413Q35802220-0C8A8F6F-0917-479D-ACEC-11616E69ACD9Q36064796-C0397A78-87DA-477D-9120-51BCD8C96B57Q36193701-A7051957-BD7C-4E23-8340-8E9FF4A22E32Q36201257-A18DCBF9-BBF1-411B-AE03-08E0229D91B0Q36216246-F0392F85-8822-4526-B73E-27F697500BC4Q36337592-69B03B9A-547F-4E0B-9E31-B30493961044Q36381561-FAE09099-E1C6-459A-A4F2-08D73C334183Q36591345-0FC61414-11E4-425B-BC86-ECEDAB4C0ADF
P50
name
Rob Pieters
@en
Rob Pieters
@nl
type
label
Rob Pieters
@en
Rob Pieters
@nl
altLabel
Pieters R
@en
Pieters R.
@en
Pieters
@en
R Pieters
@en
R. Pieters
@en
prefLabel
Rob Pieters
@en
Rob Pieters
@nl